Dergiler / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 2

The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF

Sayfa
125–129
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although pathophysiological background of this association remains to be investigated, the time courseof treatment may be a critical component of AHF treatment, and it will be important to take this factor into account in future clinical studies onAHF.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Acute heart failure (AHF) is a clinical syndrome with devastating prognosis.
📊
Temel Bulgular & Veri:Data from the REALITY-AHF revealed that early treatment with intravenous furosemide is significantly associatedwith lower in-hospital mortality.
💡
Sonuç & Katkı:Although pathophysiological background of this association remains to be investigated, the time courseof treatment may be a critical component of AHF treatment, and it will be important to take this factor into account in future clinical studies onAHF.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Acute heart failure (AHF) is a clinical syndrome with devastating prognosis. Despite considerable improvements in the treatment of chronicheart failure, most trials of new drugs for AHF, such as vasodilators, inotropes, and diuretics, have failed to show a prognostic benefit. Therefore,pharmacological treatment of AHF has changed very little, and loop diuretics have remained a cornerstone drug for decades. One of theemerging factors possibly playing an important role in AHF management is the time course of treatment. Several recent retrospective studieshave highlighted the importance of early treatment in AHF; however, at the time, support from a prospective study with an adequate number ofenrolled patients was lacking. The Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart Failure(REALITY-AHF) was the first prospective study to specifically focus on the time course of treatment in the very acute phase and its prognosticimplication in patients with AHF. Data from the REALITY-AHF revealed that early treatment with intravenous furosemide is significantly associatedwith lower in-hospital mortality. Although pathophysiological background of this association remains to be investigated, the time courseof treatment may be a critical component of AHF treatment, and it will be important to take this factor into account in future clinical studies onAHF.

🔖

Bu Makaleye Atıf Yap

KAGİYAMA, N., MATSUE, Y. (2018). The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 2, 125–129. https://ajindex.com/articles/365275

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Wong YW, Fonarow GC, Mi X, Peacock WF 4th, Mills RM, Curtis LH, et al. Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). Am Heart J 2013; 166: 349-56. [CrossRef] Green SM, Martinez-Rumayor A, Gregory SA, Baggish AL, O'Donoghue ML, Green JA, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008; 168: 741-8. [CrossRef] Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429- 39. [CrossRef] Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al.; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206. [CrossRef] Kawase T, Toyofuku M, Higashihara T, Okubo Y, Takahashi L, Kagawa Y, et al. Validation of lactate level as a predictor of early mortality in acute decompensated heart failure patients who entered intensive care unit. J Cardiol 2015; 65: 164-70. [CrossRef] Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al.; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26. [CrossRef] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-77. [CrossRef] Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008; 52: 534-40. [CrossRef] Peacock WF 4th, Fonarow GC, Emerman CL, Mills RM, Wynne J; ADHERE Scientific Advisory Committee and Investigators; Adhere Study G